Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma
Status:
Completed
Trial end date:
2018-07-31
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if lapatinib when given in combination
with temozolomide can help to control ependymoma that has come back after treatment. The
safety of this combination will also be studied.
Phase:
Phase 2
Details
Lead Sponsor:
National Institutes of Health Clinical Center (CC)
Collaborator:
CERN Foundation - Collaborative Ependymoma Research Network